Saturday 17 October 2026
Export CELZ’s income statement to Excel — free account
Creative Medical Technology Holdings, Inc.
CELZ Healthcare Biotechnology
Creative Medical Technology Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,000.00, down 45.5% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 14.6% and free cash flow fell 27.1%, each against the same quarter a year earlier.
0.74
0.08
−9.76%
Follow CELZ
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | 4 | 3 | 4 | 3 | 3 | 3 | 4 |
P/E ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.30 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | 26,422.65 | 321.12 | (77.15) | (193.07) | (2.01) | (3.97) | 2.14 | (9.09) | (4.32) |
P/S ratio |
— | 0.00 | 23,313.55 | 1,406.15 | 48.92 | 54.67 | 26.00 | 78.39 | 170.99 | 274.72 |
Altman Z″-Score (non-manufacturers) |
— | (172.98) | (190.48) | (277.45) | (661.98) | 1.36 | (2.44) | 13.80 | (11.32) | (1.04) |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | (105.78) | (67.22) | — | — | — | — | — | — |
P/Operating CF |
— | (779,882.64) | (9,807.93) | (922.02) | 141.44 | (4.96) | (1.13) | (3.42) | (1.75) | (2.41) |
P/B ratio |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.56 | 0.26 | 0.63 | 0.54 | 0.62 |
Price to Tangible BV |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.59 | 0.26 | 0.65 | 0.59 | 0.66 |
EV/Sales |
— | 0.00 | 23,316.59 | 1,412.04 | 53.13 | (46.05) | (26.44) | (41.09) | (120.12) | (142.33) |
EV/EBITDA |
— | 0.00 | 17,547.39 | 376.74 | 0.00 | 0.00 | 0.41 | 0.61 | 0.43 | 0.40 |
EV/Operating CF |
— | (107,567.26) | (2,756.42) | (192.64) | (20.11) | 2.19 | 0.53 | 0.42 | 0.45 | 0.41 |
EV/FCF |
— | (107,567.26) | (2,756.42) | (192.64) | (11.00) | 1.88 | 0.31 | 0.25 | 0.23 | 0.22 |
Quick Ratio |
0.49 | 0.01 | 0.07 | 0.01 | 0.00 | 10.21 | 2.50 | 26.89 | 18.13 | 25.30 |
Current Ratio |
0.49 | 0.01 | 0.07 | 0.01 | 0.00 | 10.22 | 5.64 | 27.65 | 18.73 | 25.97 |
Net Debt/EBITDA |
0.13 | (0.28) | 2.29 | 1.57 | (10.14) | (9.54) | 0.82 | 1.81 | 1.05 | 1.20 |
Debt/Assets |
39.57% | 124.37% | 142.94% | 200.13% | 109.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.81) | (0.11) | (0.17) | (0.13) | (0.02) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.02 | 0.37 | 0.33 | 0.26 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.58 | 0.33 | 0.08 | 0.14 | 0.01 | (0.12) | 0.77 | 1.52 | 0.97 | 0.98 |
Capex/Depreciation |
(1.06) | 0.00 | 0.00 | 0.00 | (0.24) | 0.00 | 0.00 | (1.06) | (1.81) | 0.00 |
Interest Coverage |
(118.70) | (3.12) | (0.82) | (0.60) | (0.91) | (0.73) | — | — | — | — |
| 1,414.77% | 222.15% | 438.12% | 140.55% | 151.73% | (129.86%) | (77.78%) | (40.34%) | (65.85%) | (86.53%) | |
| (411.77%) | (1,011.83%) | (4,014.61%) | (1,683.27%) | (5,818.55%) | 320.57% | (66.62%) | (35.36%) | (63.20%) | (82.81%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (84.87%) | (984.74%) | (895.02%) | (1,213.03%) |
Return on Tangible Assets |
330.22% | 110.03% | 328.41% | 99.71% | 89.86% | 198.33% | (65.76%) | (53.40%) | (94.59%) | (84.27%) |
Average Days of Receivables |
— | 365.00 | 28.17 | 12.35 | 0.00 | 10.39 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 5,418.75% | 77.65% | 0.00% | 0.00% | 124.37% | 7,075.51% | 21,895.56% | 21,825.45% | 37,663.33% |
Selling, General and Administrative Expense of Revenue |
0.00% | 18,718.75% | 844.45% | 739.09% | 706.32% | 3,376.42% | 4,450.90% | 39,558.89% | 29,447.27% | 62,725.00% |
Intangible Assets out of Total Assets |
0.31 | 0.91 | 0.34 | 0.82 | 0.86 | 0.05 | 0.02 | 0.04 | 0.08 | 0.05 |
Share Based Compensation of Revenue |
0.00% | 3,004.17% | 1.53% | 0.00% | 103.53% | 678.13% | 77.54% | 406.67% | 332.73% | 58.33% |
Graham Net Nets |
— | 0.00 | 0.00 | (0.04) | (5.02) | 1.68 | 3.79 | 1.53 | 1.70 | 1.52 |
Graham Number |
— | 1.09 | 89.73 | 37.96 | 3,115.24 | 255.12 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | 0.00% | (0.47%) | (3.65%) | (451.35%) | 333.71% | (262.78%) | (80.65%) | (160.61%) | (132.14%) |
Free Cash Flow Yield |
— | 0.00% | (0.04%) | (0.52%) | (9.87%) | (44.74%) | (323.81%) | (208.48%) | (310.63%) | (239.34%) |
Revenue per Share |
0.00 | 0.00 | 0.32 | 0.16 | 2.84 | 0.34 | 0.08 | 0.01 | 0.01 | 0.00 |
Operating CF per Share |
(0.05) | (0.08) | (2.69) | (1.17) | (7.51) | (8.51) | (7.13) | (5.70) | (3.58) | (2.46) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | (4.32) | 0.00 | 0.00 | (0.07) | (0.14) | 0.00 |
Free Cash Flow per Share |
(0.05) | (0.08) | (2.69) | (1.17) | (11.82) | (8.51) | (7.13) | (5.77) | (3.72) | (2.46) |
Cash per Share |
0.02 | 0.00 | 0.78 | 0.09 | 1.69 | 41.17 | 7.61 | 7.10 | 4.01 | 3.03 |
Shareholders Equity per Share |
(0.02) | (0.21) | (10.23) | (7.80) | (687.44) | 39.22 | 14.51 | 7.35 | 4.28 | 3.16 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.02) | (0.21) | (10.23) | (7.80) | (687.44) | 39.22 | 14.51 | 7.35 | 4.28 | 3.16 |
Free Cash Flow |
(0.46) | (0.89) | (1.05) | (1.21) | (0.68) | (2.22) | (7.80) | (8.13) | (5.50) | (5.86) |
Working Capital |
(0.23) | (2.42) | (4.16) | (8.51) | (40.42) | 9.69 | 15.43 | 9.90 | 5.81 | 7.11 |
Capital Expenditures |
(0.01) | — | — | — | (0.25) | — | — | (0.10) | (0.20) | — |
Net Current Asset Value |
(0.26) | (2.42) | (4.16) | (8.51) | (40.42) | 9.69 | 15.43 | 9.90 | 5.81 | 7.11 |
EV/EBIT |
— | 0.00 | 0.00 | 0.00 | 0.00 | 1.55 | 0.40 | 0.60 | 0.42 | 0.39 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 1.52 | 0.00 | 0.00 | 11.11 | 18.18 | 0.00 |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
(237.45%) | 45.16% | 34.98% | 17.53% | 1.76% | (10.58%) | (32.24%) | (39.98%) | (44.79%) | (39.75%) |
Accounts Receivable Turnover |
— | 0.18 | 17.28 | 21.78 | 0.00 | 21.68 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.05 | 0.25 | 0.14 | 0.15 | 0.09 | 0.01 | 0.00 | 0.01 | 0.01 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.70 | 0.43 | 1.00 | 0.00 |
Average Days of Payables |
2,578.30 | 10,840.50 | 1,720.27 | 2,573.45 | 2,531.20 | 5,805.71 | 41,846.93 | 32,170.69 | 22,688.07 | 44,911.59 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 83.06 | 130.63 | 669.17 | 182.50 | 0.00 |
Average Receivables |
— | 0.03 | 0.01 | 0.01 | — | 0.00 | — | — | — | — |
Average Payables |
— | 0.15 | 0.28 | 0.33 | 0.34 | 0.56 | 2.01 | 1.79 | 0.30 | 0.27 |
Average Inventory |
— | — | — | — | — | — | 0.01 | 0.01 | 0.00 | — |
Average Assets |
0.19 | 0.26 | 0.34 | 0.50 | 0.62 | 5.99 | 15.23 | 14.95 | 8.69 | 7.24 |
Average Common Equity |
(0.05) | (1.20) | (3.12) | (6.04) | (23.94) | (14.79) | 13.04 | 13.10 | 8.34 | 6.93 |
Columns are period end dates